Lexicon Pharmaceuticals, Inc. LXRX
At closeNov 4, 2026, 4:00 PM EST
After hours · Nov 4, 4:00 PM ET
- YTD
- +28.70%
- 1 year
- +11.28%
- Market cap
- 658.53M
- Revenue (ttm)
- 41.47M
- Profit margin
- -147.38%
- EPS (ttm)
- -0.16
- Shares out
- 444.96M
- Forward P/E
- -11.86
- YTD return
- +28.70%
- 1-year return
- +11.28%
- Volume
- 1.95M
- Avg volume
- 2.67M
- Open
- 1.50
- Previous close
- 1.46
- Day's range
- 1.46 – 1.54
- 52-week range
- 1.10 – 2.68
- Beta
- 1.03
- Analysts
- Buy
- Price target
- 3.86 (+160.5%)
- Earnings date
- Nov 5, 2026
30m 0.00 (0.00%)
Key statistics
- Enterprise value
- 865.33M
- PEG ratio
- -13.77
- Price / sales
- 24.25
- Price / book
- 5.77
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -97.60%
- Free cash flow
- -44.77M
- Total cash
- 190.61M
- Total debt
- 59.24M
- Return on equity
- -40.21%
- Short % of float
- 13.87%
- 50-day average
- 2.33
- 200-day average
- 1.78
Analyst view
Consensus: buy
- Target (low)
- 2.00
- Target (mean)
- 3.86
- Target (high)
- 6.00
- Strong buy1
- Buy2
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.0529.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.06 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.05023 | -0.06 | -0.01 | -19.45% |
| May 7, 2026 | Mar 31, 2026 | -0.04 | -0.0026 | +0.04 | +93.50% |
| Mar 5, 2026 | Dec 31, 2025 | -0.07 | -0.04 | +0.03 | +42.86% |
| Nov 6, 2025 | Sep 30, 2025 | -0.07 | -0.04 | +0.03 | +42.86% |
| Aug 6, 2025 | Jun 30, 2025 | -0.08 | 0.01 | +0.09 | +112.50% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 11, 2026 | Citigroup | main | Buy | Buy |
| Mar 23, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 10, 2026 | Citigroup | main | Buy | Buy |
| Mar 5, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 2, 2025 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 7, 2025 | Citigroup | main | Buy | Buy |
About Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- lexpharma.com
News
Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026 
Lexicon Pharmaceuticals Issues Update On Baseline Characteristics Of Patients Randomized Into Its Ongoing Pivotal Phase 3 SONATA-HCM Clinical Trial Evaluating Sotagliflozin In Patients With Symptomatic Hypertrophic Cardiomyopathy; Patient Enrollment Profile Of SONATA-HCM Is Consistent With Study’s Inclusive Design 
Lexicon Highlights Preclinical Studies Showing Biological Effects Of Sotagliflozin In Hypertrophic Cardiomyopathy And Thrombotic Disease Pathways 
Lexicon Pharmaceuticals Q2 2026 Earnings Call: Complete Transcript
Your note
Sign in to keep a note on LXRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AMOUYAL PHILIPPE | Director | Conversion of Exercise of derivative security | Jun 2, 2026 | 374,486 |
| ARTAL PARTICIPATIONS S.A.R.L. | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 29, 2026 | 0 |
| CRUM BRIAN T | General Counsel | Conversion of Exercise of derivative security | Feb 26, 2026 | 428,802 |
| DEBBANE RAYMOND | Director | Conversion of Exercise of derivative security | Jun 2, 2026 | 51,750,200 |
| EXTON MICHAEL | Chief Executive Officer | Conversion of Exercise of derivative security | Feb 26, 2026 | 298,432 |
| GRANOWITZ CRAIG B. M.D., PH.D. | Officer | Conversion of Exercise of derivative security | Feb 26, 2026 | 323,430 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Artal Group S.A. | 39.36% | 175,156,062 | 395.85M | Jun 29, 2026 |
| FMR, LLC | 11.64% | 51,782,045 | 117.03M | Jun 29, 2026 |
| Siren, L.L.C. | 9.96% | 44,303,518 | 100.13M | Jun 29, 2026 |
| Sessa Capital IM, L.P. | 4.26% | 18,960,836 | 42.85M | Jun 29, 2026 |
| Blackrock Inc. | 3.90% | 17,348,741 | 39.21M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 2.23% | 9,901,208 | 22.38M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 3.88% | 17,247,637 | 38.98M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.54% | 6,847,451 | 15.48M | Mar 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.40% | 6,209,944 | 14.03M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 1.14% | 5,083,069 | 11.49M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 0.93% | 4,127,293 | 9.33M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.61% | 2,701,371 | 6.11M | Jun 29, 2026 |